Papillary serous cystadenocarcinoma

Papillary serous cystadenocarcinoma
Synonyms
Pronounce
Field
Symptoms
Complications
Onset
Duration
Types
Causes
Risks
Diagnosis
Differential diagnosis
Prevention
Treatment
Medication
Prognosis
Frequency
Deaths

Ovarian cancers in women aged 20+.

Papillary Serous Cystadenocarcinoma

Papillary serous cystadenocarcinomas are the most prevalent form of malignant ovarian cancer, accounting for approximately 26 percent of ovarian tumors in women over the age of 20 in the United States. Characterized by their aggressive nature, these tumors often present challenges in early detection and treatment.

Overview

Papillary serous cystadenocarcinomas are known for their malignant potential and tendency to metastasize. They are commonly diagnosed in advanced stages, as early signs of the disease are typically absent. The spread of these tumors often occurs along the peritoneum, contributing to the complexity of treatment.

Histopathology

Histopathological examination of papillary serous cystadenocarcinomas can reveal distinct features such as:

• Psammoma bodies - Calcified structures that are often present in these types of tumors.

Diagnosis

Diagnosis of papillary serous cystadenocarcinoma typically involves a combination of:

• Pelvic examinations
• Imaging studies such as Ultrasound, CT scans, or MRI
• CA-125 blood test, which may show elevated levels in the presence of ovarian cancer
• Biopsy and histopathological analysis to confirm the presence of cancerous cells

Treatment

The standard treatment for papillary serous cystadenocarcinoma often includes:

• Surgery to remove as much of the tumor as possible
• Chemotherapy to target cancer cells that may have spread beyond the ovaries
• Targeted therapies and hormone therapies may also be used depending on the individual case and tumor characteristics

Prognosis

The prognosis for patients with papillary serous cystadenocarcinoma can vary based on the stage at diagnosis and the effectiveness of treatment. Generally, the five-year relative survival rate serves as a benchmark for prognosis, with early detection and treatment improving outcomes.

See Also

• Ovarian cancer
• Gynecologic oncology
• Cancer staging
• Oncology treatments

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

   This article is a  stub. You can help WikiMD by expanding it!